Project Grant R43AI136220

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,942 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Georgia Tech Research Corp to develop self-assembled peptide nanoparticles as a universal influenza vaccine platform. The goal is to use these nanoparticles to present conserved viral antigens, including hemagglutinin stalk, matrix protein 2 ectodomain, and nucleoprotein, in order to elicit broad, protective immune...

This Project Grant award from the U.S. Department of Agriculture's (USDA) National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program provides $649,896 to the University of Illinois for research on an mRNA vaccine cocktail to protect against diverse influenza A virus (IAV) strains in livestock and humans. The goal is to develop a universal influenza vaccine that can induce broad, protective immunity against the genetically diverse IAV subtypes,...

The University of Missouri System, under a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program, is developing safe and effective live attenuated swine influenza vaccines using Newcastle disease virus (NDV) as the vector. The project aims to address the challenges with current swine influenza vaccines, which often fail to provide cross-protection against diverse virus strains. The key products and...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. The project aims to combine the advantages of a closely matched seasonal influenza vaccine with a universal influenza vaccine to provide more robust and durable protection, especially for the elderly and immunocompromised...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...

The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple...

The federal Cooperative Agreement award, funded by the Advanced Research Projects Agency for Health (ARPA-H) under CFDA 93.384, aims to develop a broad vaccine that can protect against multiple emergent alphavirus infections. The $62,534,750 award to Vanderbilt University will leverage advanced computational biology, structural biology, vaccinology, virology, and immunology techniques to design and test novel vaccine candidates. The project's key objectives are to: Create hetero-nanoparticle...

This $15,981,588 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases aims to develop pan-coronavirus vaccines. Led by Washington University, the collaborative program includes eleven laboratories seeking to design optimized B and T cell antigens conferring broad immunity against sarbecoviruses and merbecoviruses. The three-year award beginning September 2022 supports three integrated research projects and two centralized cores. Project 1...

The federal Cooperative Agreement award U19AI181984, totaling $44,108,652.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of this 3-year award is to develop vaccines and antibody-based treatments for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families, with a focus on prototype viruses such as human parainfluenza virus 3 (HPIV3), Oropouche virus...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to gain mechanistic insights into how vaccine adjuvant formulation can overcome immunodominance and stimulate broadly protective antibody responses against influenza. The $1,395,922 award to the Trustees of Indiana University, doing business as Indiana University Indianapolis, will fund research to understand how a Toll-like Receptor 7 (TLR7)...